STARPHARMA HOLDINGS LTD.

WKN
796461
ISIN
AU000000SPL0
  • Aktien
  • Aktien International
Es ist ein Fehler beim Laden der Chart-Daten aufgetreten.

0,720 EUR Verkauf

0,753 EUR Kauf

+0,03 Abs.

+3,8 % Rel.

18.01.2019 22:13Lang & Schwarz
  • Vortag / Eröffnung 0,710 / 0,710
  • Hoch / Tief (1 Tag) 0,737 / 0,710
  • Hoch / Tief (1 Jahr) 1,075 / 0,600
  • 1 Woche +2,5 %
  • 1 Monat -14,9 %
  • 1 Jahr -17,3 %

Ausgewählter Top-Trade

Für dieses Wertpapier gab es noch keinen Top-Trade.

Beliebtheitsindikator

Es ist ein Fehler beim Laden der Chart-Daten aufgetreten.

Trading-Sentiment

Es ist ein Fehler beim Laden der Chart-Daten aufgetreten.

Neueste Kommentare

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications. Starpharma’s lead products are based on VivaGel ® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited and Okamoto Industries. Inc., to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect TM brand. In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets. In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate.
mehr anzeigen
Lassen Sie sich nichts entgehen!
Um sämtliche Kommentare in diesem Wertpapier zu sehen, erstellen Sie sich bitte einen Account.